Jun 23, 2025, 12:40
A New Era in Hemophilia A Prophylaxis: Dr. Shima Presented Groundbreaking Phase I/II Results for NXT007
NXT007 Hemophilia A Prophylaxis took center stage today when Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on X.
“A New Era in Haemophilia A Prophylaxis. Dr. Shima presented groundbreaking phase I/II results for NXT007, a next-generation bispecific antibody: 30 patients with severe haemophilia A (no inhibitors), age range: 12-65 years (median age 39.5 years), subcutaneous dosing: 0.072-1.08 mg/kg every 4 weeks.
Higher dose cohorts (B-3, B-4) achieved FVIII-equivalent activity in the normal range.
Well-tolerated profile with no thromboembolic events, but high anti-drug antibody prevalence: 22/30 patients (73%) and effect on plasma concentrations in 2/22.”
Stay up to date with Hemostasis Today
-
Oct 9, 2026, 11:06Nobles Green: How siRNA Therapy Helps the Body Form Stronger Clots
-
Oct 9, 2026, 10:53Switching From Emicizumab to Denecimig in Hemophilia A – Rare Disease Advisor
-
Oct 9, 2026, 10:40What New U.S. Data Reveal About GT – Glanzmann’s Research Foundation
-
Oct 9, 2026, 10:32Anjali Pandey: The Morphologic Clues to MDS With del(5q)
-
Oct 9, 2026, 10:13Reza Shojaei: 5 Leadership Responsibilities for a Sustainable Plasma Ecosystem
-
Oct 9, 2026, 08:38Johannes Gratz: Perioperative Care in Factor VII Deficiency – Treating the Patient, Not the Number
-
Oct 9, 2026, 08:28Ghanim Fajish: Vascular Cells May Retain a Prothrombotic Memory of Oxidative Stress
-
Oct 9, 2026, 07:43Mehmet Cilingiroglu: The First Diagnosis of Coronary Thrombosis in a Living Patient
-
Oct 9, 2026, 07:21Federico Ravaioli: 40 kPa Spleen Stiffness May Help Avoid Endoscopy in Chronic PVT